###### Strengths and limitations of this study

-   The study was closely aligned to practice and protocols tested could be readily translated into primary care services.

-   Although this was a single-centre study, substantial controls were applied to provide quality evidence of effects.

-   The study demonstrated the breadth of behavioural influences integral to achieving weight loss and clinical outcomes.

-   Rigorous statistical analyses were applied to the evaluation of primary outcomes, including a sensitivity analysis to confirm effects.

-   As practice-oriented research, retention strategies were not applied, with higher than anticipated loss to follow-up following the intensive phase.

Introduction {#s1}
============

The prevention and management of chronic non-communicable disease (CNCD) is a challenge for health services.[@R1]Given the links to disease pathology, identifying overweight as a problem is an important first step.[@R2] Primary care is an ideal setting for the clinical management of obesity, yet relevant studies are scarce,[@R3] and measuring or recording weight in this setting appears suboptimal.[@R4] In addition, weight management may require a more shared sense of decision making,[@R5] and a broader approach, including the expertise of relevant allied health professionals.[@R6] For example, dietitians may provide expertise on nutritional factors other than dietary energy that influence weight loss and chronic disease risk factors,[@R7] such as dietary patterns,[@R8] significant foods,[@R9] and nutrients such as fibre,[@R10] fatty acids[@R11] and sodium.[@R12]

Health behaviours that can significantly lower disease risk are central to the management of chronic disease.[@R13] There is convincing evidence that focusing on diet, physical activity and behaviour will have the best effects on overweight.[@R14] Obese individuals who lose just 5% of their body weight (the target for American College of Cardiology/American Heart Association clinical guidelines[@R2]) have significant improvements in risk factors for type 2 diabetes and cardiovascular disease, including improved insulin sensitivity and reduced fat in the liver.[@R15] However, there are underlying metabolic problems and weight regain invariably follows.[@R16] This suggests obesity itself is a chronic condition requiring acute effective treatments repeated at intervals[@R16] with the provision of consistent positive reinforcement to address associated complex psychological factors.[@R18] There is little research on holistic treatments that integrate diet, exercise and psychological support[@R19] and research is needed to test novel protocols in this area.[@R20] In a feasibility trial comparing usual care with an interdisciplinary model, we found high eligibility (83%) and completion (87%) rates and a preliminary effect of −3.98 kg greater weight loss over 3 months (95% CI 6.17 to 1.79, p=0.002).[@R22] The next research question was whether weight loss could be achieved in a larger cohort and over a longer time period. The objective of the current trial was to determine the effectiveness of a novel interdisciplinary treatment compared with usual care on weight loss in overweight and obese adult volunteers. We hypothesised that a model of care with physician oversight that integrates the expertise of dietitians, with exercise physiologists and psychologists will be more effective than general advice provided by a practice nurse (usual care). Further, the provision of a supplement of a significant healthy food may enhance this effect and influence the overall diet.

Methods {#s2}
=======

Study oversight {#s2a}
---------------

The trial is registered with the Australian and New Zealand Clinical Trial Registry (ANZCTRN12614000581662). Study oversight was provided by the senior clinical investigative team.

Study participants {#s2b}
------------------

Recruitment was conducted through communications and advertising in the local media. Respondents who were permanent residents of the Illawarra region, aged 25--54 years, community dwelling and with a body mass index (BMI) 25--40 kg/m^2^ were included. Exclusion criteria were being unable to communicate in English; having severe medical conditions impairing the ability to participate in the study or thought to limit survival to 1 year, having reported illegal drug use or regular alcohol intake associated with alcoholism (\>50 g/day); or other major impediments to participation.

Trial design {#s2c}
------------

This was a community-specific (single-centre), randomised, assessor blinded trial, comparing outcomes between intervention and control groups at 0 months, 3 months, 6 months, 9 months, 12 months. Full details of the study protocol and baseline results are reported elsewhere.[@R23] Briefly, all participants attended the clinic for counselling on seven occasions (0 months, 1 months, 2 months, 3 months, 6 months, 9 months, 12 months) and received quarterly support phone calls. Assessment and treatment protocols were devised by the research team including physicians, dietitians, exercise physiologists and psychologists. Measurements were undertaken separately at these time points. Body weight (kg) was measured at each visit in an upright position (minimal clothing, no shoes) using scales with a bioelectrical impedance component for estimating body fat (%) (Tanita TBF-662, Wedderburn, Ingleburn, New South Wales, Australia). Systolic blood pressure (SBP) and diastolic blood pressure were measured at 0 months, 3 months and 12 months using the Omron BP-203RPEIII VP-1000 device (Omron Healthcare, Kyoto, Japan). Measurements are collected at the end of 5 min resting period in supine position. Fasting blood lipids (cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides), fasting blood glucose and serum HbA1c were assessed through a registered pathology service (Southern IML Pathology) quarterly. For 24 hours urinary sodium assessments, a 24 hours urine sample was provided at 0 months, 3 months and 12 months. Dietary intake was assessed using a diet history interview[@R24] and physical activity using the International Physical Activity Questionnaire (IPAQ)[@R25] and via a pedometer (Yamax Digiwalker SW200, Pedometers Australia) worn for a 4-day period every quarter. A range of psychological assessments were applied, including the Physical and Mental Health 12-Item Short-Form Health Survey (SF-12) (12 questions),[@R26] Depression Anxiety Stress Scale (short form 21 questions),[@R27] and Acceptance and Action Questionnaire for Weight-related problems (11 questions) (AAQW)[@R28] at 0 months, 3 months and 12 months.

Participants were randomly assigned to usual care (C, general advice), intervention (I, interdisciplinary advice) and intervention + food supplement (IW, I+30 g walnuts/day). Usual care involved a nurse providing general advice based on the Australian Guide to Healthy Eating (AGHE)[@R29] and National Physical Activity Guidelines.[@R30] Phone contact at quarterly intervals was also made by the study administrator delivering semiscripted patient-centred support of short duration. In the intervention counselling session an accredited practising dietitian negotiated changes in specific food choices based on a diet history assessment and materials that referred to the food groups outlined in AGHE (vegetables, fruits, grains, protein rich foods, dairy foods, oils). This consultation included advice to increase physical activity and reduce sedentary behaviour by identifying opportunities in leisure, occupation and household activities, with additional categorical guidance prepared by the exercise physiologist following exercise assessment. The psychologist developed a workbook for participants and trained health coaches to deliver related scripted calls of short (15 min) duration at quarterly intervals. The psychological coaching component was based on principles from Acceptance and Commitment Therapy[@R31] and involved clarification of underlying values to increase motivation related to weight loss, increasing mindfulness and awareness to facilitate better health choices, and self-compassion to promote continued valued-action even in the presence of setbacks.

Randomisation was performed remotely in randomly allocated blocks of three, six or nine by an investigator unrelated to the clinic. A computer generated randomisation sequence was used (STATA V.12, StataCorp, College Station, Texas, USA). The randomisation was stratified according to sex and BMI (low BMI ≤30 and high BMI \>30). The randomisation list was provided to the study team who added eligible participants sequentially for each of the strata. Participants were blinded to their randomised allocation and only advised they would be seen by a health practitioner.

Effectiveness outcomes {#s2d}
----------------------

All end points compared baseline data with 12-month results. The primary outcome was body weight (kg). Secondary outcomes were fasting blood lipids, glucose and haemoglobin A1c (HbA1c), SBP, dietary intake, measures of physical activity and psychological well-being.

Statistical analysis {#s2e}
--------------------

Outcomes were analysed using mixed models. The primary outcome variable weight was analysed using a published model building procedure.[@R32] Initially a simple model with main effects and a group by time interaction was considered. Initial data exploration suggested quadratic and cubic terms may be needed and these were added in turn and tested with likelihood ratio tests to determine improvement in model fit. Random effects for both intercept and slope were included in the weight model. A similar procedure was followed for all other variables. Significant higher order interaction terms were followed up by analysis of covariance (ANCOVA) to determine differences between groups at each time point with baseline value as a covariate. Gender was included as a covariate in the body composition models. As the dropout rate at the end of the follow-up period (12 months) was substantial, several sensitivity analyses were performed. First multiple imputation of 100 data sets was used to verify the significance of the difference between the groups at all time points. The imputation model included group, age and gender, as well as weight at each time point. A complete case analysis, last observation carried forward (LOCF) and baseline observation carried forward (BOCF) were also performed. Model building was performed using LMER in the LME4 package of R (RStudio V.0.99.489, RStudio). Multiple Imputation was performed in SAS (V.9.4 SAS Institute, Cary, North Carolina, USA) using PROC MI, PROC MIXED and MIANALYSE, for the ANCOVA. F tests for the 100 multiple imputations using PROC MIXED were combined using the package MICEADDS in R.

Results {#s3}
=======

Participants {#s3a}
------------

Recruitment began in May 2014 and the last participant completed in May 2016. Surveys were sent to 718 respondents, 439 of whom underwent baseline assessments. n=377 were randomised into the C (n=126), I (n=125) and IW groups (n=126). The intensive phase was completed by 298 participants (withdrawal rate 18%) and the 12 months follow-up by n=178 participants (withdrawal rate 39%) ([figure 1](#F1){ref-type="fig"}). Screening and baseline data are reported elsewhere.[@R23] The sample comprised mostly obese (BMI 32 (29--35) kg/m^2^), non-smoking (98%) well educated (85% postschool qualifications) women (74%) of median age 45 (37--51) years. They also suffered from anxiety (26.8%) and depression (33.7%) and were treated for hypertension (25%). Metabolic syndrome was identified in 34% of participants.[@R33]

![Participant flow in the HealthTrack randomised controlled trial.](bmjopen-2016-014533f01){#F1}

Participants attended the Clinical Trials Unit of the Illawarra Health and Medical Research Institute. After randomisation 67 participants withdrew, with most (75%) citing an inability to commit time and/or personal reasons. The next major withdrawal (n=49) occurred after the 3-month intensive phase for similar reasons. Attendance gradually reduced for all groups but IW participants attended more, and were more likely to complete the phone coaching calls than the I group (at quarters 2, 3, 4; p\<0.05). Less than a quarter of participants were on medications for glucose, lipids and blood pressure. There were no differences between groups for medication use (p\>0.05) ([table 1](#T1){ref-type="table"}).

###### 

Number (%) of participants reporting medication during the HealthTrack study

  Medication type                 Control   Intervention   Intervention + walnuts   p value[\*](#tblfn1){ref-type="fn"}
  ------------------------------- --------- -------------- ------------------------ -------------------------------------
  Antihypertensive (n (%))                                                          
   Baseline                       14 (11)   20 (16)        17 (14)                  0.521
   3 months                       10 (10)   16 (16)        17 (17)                  0.410
   6 months                       7 (10)    10 (15)        12 (14)                  0.654
   9 months                       6 (10)    8 (15)         13 (17)                  0.491
   12 months                      6 (10)    9 (20)         13 (18)                  0.267
  Hypoglycaemic/insulin (n (%))                                                     
   Baseline                       6 (5)     4 (3)          5 (4)                    0.945
   3 months                       6 (6)     3 (3)          5 (5)                    0.584
   6 months                       2 (3)     2 (3)          4 (5)                    0.819
   9 months                       1 (2)     3 (6)          3 (4)                    0.563
   12 months                      1 (2)     3 (7)          3 (4)                    0.429
  Hypolipidaemic (n (%))                                                            
   Baseline                       15 (12)   10 (8)         7 (6)                    0.201
   3 months                       14 (15)   8 (8)          7 (7)                    0.147
   6 months                       10 (14)   6 (9)          5 (6)                    0.190
   9 months                       9 (15)    6 (11)         5 (7)                    0.287
   12 months                      10 (16)   5 (11)         3 (4)                    0.064

\*χ^2^ test

Primary outcomes {#s3b}
----------------

### Weight loss {#s3b1}

After 12 months weight reduced in all groups with a significant difference between groups (p=0.0002) ([tables 2 and 3](#T2 T3){ref-type="table"}). The primary analysis model including group, gender and time, found a quadratic time by group interaction. The effect was seen with the IW group showing initial weight loss and then a gain from 6 months, while the other groups maintained their weight loss over time ([figure 2](#F2){ref-type="fig"}). Post hoc analysis on complete cases indicated significantly greater weight loss in I and IW compared with C at 3 months (−1.2 kg, p=0.045 I; −1.3 kg, p=0.025 IW) and at 6 months for IW (−2.1 kg; p=0.010). The ANCOVA compared the groups using a mixed model on the actual data and the combined estimates for 100 imputations ([table 2](#T2){ref-type="table"} and [supplementary materials](#SP1){ref-type="supplementary-material"}). A sensitivity analysis confirmed the effects ([table 3](#T3){ref-type="table"}). An ANCOVA on complete cases for the 12-month weight change adjusted for baseline weight, gender and age showed an effect approaching significance p=0.056 reflecting a difference between the C-IW group of −2.2 kg (95% CI −4.6 to 0.1 kg, p=0.068) compared with differences between the C-I groups −1.9 kg (95% CI −4.5 to 0.7 kg, p=0.228) and the I and IW groups −0.3 kg (95% CI −2.8 to 2.2 kg, p=1.00).
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###### Supplementary Appendix 1

###### 

Effectiveness end points for the intention-to-treat population‡

  Variable                                                        Control                           Intervention                      Intervention + walnuts      Group     Time         Group x time
  --------------------------------------------------------- ----- --------------------------- ----- --------------------------- ----- --------------------------- --------- ------------ --------------
  Body weight, mean (SD), kg                                                                                                                                      0.644     0.004(3)     \<0.001
   Baseline                                                 126   91.8 (14.7)                 125   91.9 (15.2)                 126   91.4 (15.6)                                        
   3 months                                                 96    90.0 (14.1)                 99    90.3 (15.3)                 103   88.3 (14.7)                                        
   12 months                                                61    87.8 (14.9)                 45    86.5 (17.8)                 72    87.9 (14.2)                                        
  Body fat, median (IQR), %                                                                                                                                       0.599     0.070(3)     0.022
   Baseline                                                 125   41.3 (36.2--45.1)           125   41.4 (35.4--46.1)           125   41.4 (36.2--46.1)                                  
   3 months                                                 95    41.0 (35.0--44.6)           99    39.2 (33.8--45.1)           103   39.8 (34.7--43.0)                                  
   12 months                                                61    40.7 (32.0--43.3)           45    37.0 (31.8--41.9)           72    38.2 (33.9--43.5)                                  
  Systolic blood pressure, median (IQR), mm Hg\*                                                                                                                  0.441     \<0.001(2)   0.551
   Baseline                                                 126   123 (113--132)              124   124 (114--134)              125   123 (114--134)                                     
   3 months                                                 93    118 (109--129)              96    119 (109--131)              102   119 (110--127)                                     
   12 months                                                61    116 (109--127)              45    118 (106--128)              71    123 (111--131)                                     
  Glucose, median (IQR), mmol/L                                                                                                                                   0.340     \<0.001(2)   0.399
   Baseline                                                 126   5.2 (4.9--5.6)              124   5.2 (4.9--5.7)              126   5.2 (4.9--5.8)                                     
   3 months                                                 69    5.2 (5.0--5.5)              69    5.2 (4.9--5.7)              84    5.2 (4.9--5.6)                                     
   12 months                                                52    5.5 (4.9--5.7)              37    5.3 (5.0--5.7)              64    5.3 (5.0--5.7)                                     
  HbA1c, median (IQR), (%)                                                                                                                                        0.301     0.003(3)     0.407
   Baseline                                                 126   5.2 (5.0--5.5)              125   5.2 (4.9--5.4)              126   5.1 (4.9--5.4)                                     
   3 months                                                 69    5.3 (5.1--5.4)              69    5.2 (5.0--5.4)              84    5.2 (5.0--5.5)                                     
   12 months                                                52    5.2 (5.0--5.4)              37    5.1 (4.9--5.4)              63    5.1 (4.9--5.4)                                     
  Total cholesterol, median (IQR), (mmol/L)                                                                                                                       0.193     \<0.001(3)   0.135
   Baseline                                                 126   5.3 (4.7--6.0)              124   5.0 (4.4--5.8)              126   5.1 (4.6--5.7)                                     
   3 months                                                 70    5.2 (4.4--5.6)              69    5.0 (4.4--5.5)              83    4.8 (4.3--5.6)                                     
   12 months                                                52    5.0 (4.2--5.6)              37    5.4 (4.5--6.0)              64    5.4 (4.6--5.8)                                     
  Triglycerides, median (IQR), (mmol/L)                                                                                                                           0.005     0.142        0.368
   Baseline                                                 125   1.3 (0.9--1.6)              124   1.1 (0.8--1.6)              126   1.1 (0.8--1.5)                                     
   3 months                                                 70    1.3 (0.9--1.6)              69    1.2 (0.9--1.8)              83    1.0 (0.8--1.4)                                     
   12 months                                                52    1.3 (0.9--1.6)              37    1.2 (0.8--1.7)              64    1.1 (0.9--1.6)                                     
  HDL, median (IQR), (mmol/L)                                                                                                                                     0.236     \<0.001(3)   0.098
   Baseline                                                 126   1.3 (1.1--1.7)              124   1.4 (1.2--1.6)              126   1.4 (1.2--1.7)                                     
   3 months                                                 70    1.3 (1.0--1.6)              69    1.3 (1.1--1.6)              83    1.4 (1.2--1.8)                                     
   12 months                                                52    1.3 (1.1--1.6)              37    1.5 (1.2--1.8)              64    1.5 (1.2--1.8)                                     
  Cholesterol:HDL ratio, median (IQR)                                                                                                                             0.036     \<0.001      0.739
   Baseline                                                 125   3.9 (3.0--4.7)              124   3.5 (3.1--4.4)              126   3.6 (2.9--4.3)                                     
   3 months                                                 70    4.0 (3.3--4.8)              68    3.8 (3.1--4.5)              83    3.4 (2.7--4.1)                                     
   12 months                                                52    3.8 (3.0--4.2)              37    3.3 (2.9--4.4)              64    3.5 (2.9--4.4)                                     
  LDL, median (IQR), (mmol/L)                                                                                                                                     0.516     \<0.001(3)   0.295
   Baseline                                                 123   3.2 (2.7--3.7)              123   3.0 (2.4--3.6)              126   3.1 (2.6--3.7)                                     
   3 months                                                 69    3.2 (2.4--3.8)              69    3.1 (2.5--3.4)              83    2.8 (2.3--3.5)                                     
   12 months                                                52    3.1 (2.3--3.6)              37    3.1 (2.4--4.0)              64    3.2 (2.5--4.0)                                     
  MET-mins/week (IPAQ), median (IQR)\*                                                                                                                                                   
   Baseline                                                 124   876 (396--1523)             123   918 (396--1551)             124   1040 (563--2329)            0.053     \<0.001      0.341
   3 months                                                 92    1461 (793--2486)            94    1540 (842--2635)            102   2020 (1236--3125)                                  
   12 months                                                61    1782 (807--3451)            46    2009 (924--3015)            77    1678 (827--3732)                                   
  Energy, median (IQR), kJ/day\*                                                                                                                                  0.095     \<0.001(2)   0.444
   Baseline                                                 126   9400.2 (7840.5--11 574.3)   125   8647.5 (7158.2--10 993.8)   126   8932.9 (7458.3--10 785.5)                          
   3 months                                                 93    7443.8 (6479.0--9087.9)     97    6891.1 (6045.1--8700.3)     103   7264.4 (6239.3--8444.5)                            
   12 months                                                60    7864.7 (7014.0--9345.7)     44    7184.9 (5754.3--9078.2)     71    7805.5 (6622.9--9718.9)                            
  Fibre, median (IQR), g/day                                                                                                                                      0.989     0.059        0.005
   Baseline                                                 126   26.1 (21.7--33.3)           125   25.2 (21.5--31.1)           126   25.0 (19.8--32.2)                                  
   3 months                                                 93    24.6 (19.1--30.6)           97    27.0 (22.0--33.1)           103   26.7 (22.2--32.5)                                  
   12 months                                                60    22.9 (19.7--32.5)           44    26.8 (22.2--30.1)           71    26.5 (20.6--32.1)                                  
  P:S ratio, median (IQR)\*                                                                                                                                       \<0.001   \<0.001(2)   \<0.001 (2)
   Baseline                                                 126   0.4 (0.3--0.5)              125   0.4 (0.3--0.5)              126   0.4 (0.3--0.5)                                     
   3 months                                                 93    0.5 (0.4--0.7)              97    0.5 (0.4--0.7)              103   1.3 (0.9--1.8)                                     
   12 months                                                60    0.5 (0.3--0.6)              44    0.5 (0.4--0.7)              71    0.8 (0.6--1.1)                                     
  Quality of life (SF-12), physical summary, median (IQR)                                                                                                                                
   Baseline                                                 126   49.3 (43.1--54.4)           124   49.6 (45.0--54.1)           125   51.1 (44.8--55.2)           0.027     \<0.001      0.660
   3 months                                                 91    51.3 (45.1--55.9)           96    51.0 (42.9--54.6)           102   53.5 (46.6--56.4)                                  
   12 months                                                60    54.3 (48.6--57.4)           44    52.6 (44.2--57.5)           69    54.0 (51.7--57.4)                                  
  Quality of life (SF-12), mental summary, median (IQR)                                                                                                                                  
   Baseline                                                 126   48.7 (41.3--53.5)           124   48.4 (37.7--55.0)           125   47.5 (39.4--53.9)           0.772     0.002 (2)    0.788
   3 months                                                 91    51.0 (45.6--56.7)           96    49.9 (43.1--56.4)           102   51.7 (44.9--57.2)                                  
   12 months                                                60    51.9 (41.4--57.1)           44    54.7 (44.5--56.5)           69    51.1 (42.3--55.2)                                  

Mixed model. (2) quadratic term (3) cubic term

\*Natural logarithm (ln) transformed prior to analysis

‡ results for the following variables are presented in [supplementary materials](#SP1){ref-type="supplementary-material"}: diastolic blood pressure, steps, per cent energy from protein, total fat, carbohydrate, and alcohol, urinary sodium excretion, DASS-21, AAQW.

AAQW, Acceptance and Action Questionnaire for Weight-related problems; DASS-21, Depression Anxiety Stress Scale (short form 21 questions); HbA1c, haemoglobin A1c; HDL, high-density lipoprotein; IPAQ, International Physical Activity Questionnaire; LDL, low-density lipoprotein; METS, metabolic equivalents; P:S ratio, polyunsaturated:saturated ratio; SF-12, 12-Item Short-Form Health Survey.

###### 

Sensitivity analysis, comparison of differences in weight between groups at each time point

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Method                             3                                                                     6                                                                 9                                                                 12                                          P (interaction)
  ---------- ----------------------- ----------------------- --------------------- ----------------------- --------------------- --------------------- --------------------- --------------------- --------------------- --------------------- --------------------- --------------------- -----------------
  Mixed      **−1.25\***\            **−1.11\***\            **−0.13**\            **−2.20 \*\***\         **−1.53**\            **−0.67**\            **−1.98**\            **−1.67**\            **−0.31**\            **−1.91**\            **−1.72**\            **−0.19**\            **\<0.001**
             **(−2.35 to --0.15)**   **(−2.23 to --0.00)**   **(−1.23 to 0.96)**   **(−3.90 to --0.49)**   **(−3.36 to 0.30)**   **(−2.42 to 1.08)**   **(−3.95 to 0.00)**   **(−3.80 to 0.46)**   **(−2.32 to 1.71)**   **(−4.06 to 0.25)**   **(−4.15 to 0.71)**   **(−2.54 to 2.17)**   

  MI         −1.27\*\*\              1.04\*\                 −0.23\                −1.82\*\*\              −1.26\                −0.56\                −1.69\*\              −1.46\*\              −0.24\                −1.15\                −1.06\                −0.11\                0.002
             (−2.17 to --0.37)       (−1.91 to --0.16)       (−1.12 to 0.65)       (−3.14 to --0.50)       (−2.57 to 0.04)       (−1.88 to 0.76)       (−3.22 to --0.16)     (−2.92 to --0.00)     (−1.72 to 1.24)       (−2.77 to 0.47)       (−2.57 to 0.47)       (−1.65 to to .43)     

  Complete   −1.70\*\*\              −1.14\                  −0.56\                −2.30\*\                −1.30\                −1.00\                −2.22\*\              −1.89\                −0.33\                −1.61\                −1.40\                −0.21\                \<0.001
             (−3.06 to --0.33)       (−2.66 to 0.38)         (−1.99 to 0.88)       (−4.28 to --0.32)       (−3.51 to 0.91)       (−3.08 to 1.07)       (−4.44 to 0.00)       (−4.36 to 0.58)       (−2.65 to 1.99)       (−3.90 to 0.68)       (−3.95 to 1.16)       (−2.19 to 0.68)       

  LOCF       −1.11\*\                −0.95\*\                −0.15\                −1.57\*\*\              −1.05\                −0.52\                −1.44\                −1.27\                −0.18\                −1.04\                −1.09\                0.04\                 \<0.001
             (−2.02 to --0.19)       (−1.87 to --0.04)       (−1.07 to 0.76)       (−2.77 to --0.36)       (−2.26 to 0.16)       (−1.73 to 0.69)       (−2.74 to --0.15)     (−2.56 to 0.26)       (−1.47 to 1.12)       (−2.33 to 0.24)       (−2.37 to 0.20)       (−1.24 to 1.33)       

  BCF        −1.11\*\                −0.95\*\                −0.15\                −1.73\*\*\              −0.78\                −0.96\                −1.40\*\*\            −0.64\                −0.76\                −1.30\*\              −0.46\                −0.84\                \<0.001
             (−2.02 to --0.19)       (−1.87 to --0.04)       (−1.07 to 0.76)       (−2.87 to --0.59)       (−1.92 to 0.36)       (−2.09 to 0.19)       (−2.53 to --0.28)     (−1.78 to 0.49)       (−1.89 to 0.37)       (−2.45 to --0.15)     (−1.61 to 0.70)       (−2.00 to 0.31)       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*\*\<0.01, \*\<0.05

BCF, baseline observation carried forward; Complete, complete analysis; LOCF, last observation carried forward; MI, multiple imputation, using groups, age, gender and weight at each time point. Bolded results indicate the mixed model (used as the primary analysis).
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### Achievement of 5% weight loss target {#s3b2}

χ^2^ Analyses indicated significant differences in the proportion of participants achieving the clinically significant effect of 5% weight loss. At 3 months, 6 months and 9 months the proportion achieving 5% weight loss in the C group was lower than expected (p=0.04, 0.03, 0.03, respectively), although there was no difference at 12 months (p=0.091) with 33% IW, 38% I and 20% C meeting the 5% target. At 6 months the number in the IW group was higher than expected (p=0.03), consistent with the primary analysis. Likewise there was a group difference in change in per cent body fat (interaction effect p=0.022) ([table 2](#T2){ref-type="table"}).

Secondary outcomes {#s3c}
------------------

### Clinical effects {#s3c1}

SBP decreased between baseline and 3 months but then remained unchanged ([table 2](#T2){ref-type="table"}). Changes in SBP also reflected patterns of sodium excretion (a marker of dietary intake) decreasing from baseline to 3 months (p\<0.001) and increasing to 12 months (p=0.002). Likewise, fasting blood glucose was lower than baseline at 3 months (p=0.040) and 6 months (p\<0.001), and then remained lower than 12 months (p=0.003). HbA1c at 12 months was lower than the baseline value (p=0.031).

In keeping with this pattern of effects, total cholesterol and LDL concentrations were lowest for the sample at 3 months (p\<0.001; p≤0.031, respectively) and at 6 months they remained lower than baseline (p=0.020; p=0.034, respectively). The cholesterol: HDL ratio decreased particularly after 6 months, while HDL- values first dropped at 3 months then returned to greater than baseline at 12 months (p≤0.021). The group effect for total cholesterol showed a lower overall mean for the IW group compared with controls (p=0.001) and I (p=0.037) ([table 2](#T2){ref-type="table"}).

### Behavioural effects {#s3c2}

As with the pattern of weight change, reported energy and total fat intakes (as a per cent of energy) were lower than baseline at 3 months (p\<0.001) and still at 12 months (p\<0.001), but they increased between 3 months and 12 months (p=0.020) ([table 2](#T2){ref-type="table"}). Changes in per cent energy from protein were the opposite for dietary fat. The value was higher than baseline at 3 months and 12 months (p\<0.001), but lower at 12 months than 3 months (p=0.04). Per cent energy from carbohydrate reduced from baseline to 12 months (p=0.002), and from alcohol (p=0.012) decreased from baseline to 12 months (p=0.041). The only reported difference between groups was for the polyunsaturated:saturated (P:S) fatty acid ratio, where the the IW group showed a higher value over time compared with the other groups (interaction effect p\<0.001).

The time effects for increased physical activity were stronger in self-reported MET-Mins/week (IPAQ) (p\<0.001; significantly higher than baseline at all time points, [table 2](#T2){ref-type="table"}) than measurements of steps/day (p=0.046) ([supplementary materials](#SP1){ref-type="supplementary-material"}). The changes in diet and physical activity were accompanied by increases in scores for positive psychological parameters (Quality of Life, QoL, [table 2](#T2){ref-type="table"}) and decreases for negative parameters (DASS-21; AAQW, [supplementary materials](#SP1){ref-type="supplementary-material"}). The IW group scored highest for QoL (SF-12) physical summary scores throughout the study period (group effect p=0.027). The QoL (SF-12) mental summary score increased after 3 months, with differences from baseline to 12 months (time effect p=0.002). The DASS-21 and AAQW scores were lower at 12 months (p\<0.001) but the significant decreases occurred at 3 months (p\<0.001) ([supplementary materials](#SP1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

Main findings {#s4a}
-------------

Despite the same intensity of intervention and a focus on national diet and physical activity guidelines, the interdisciplinary protocol produced greater and more clinically significant effects on weight loss than usual care ([figure 2](#F2){ref-type="fig"}). Although there were repeated attempts to retrieve participants who failed to attend visits, attrition was higher than expected, so multiple approaches including random effects mixed model analyses were applied as this would assure quality reporting required of clinical trials.[@R34] The ANCOVA compared the groups using a mixed model on the actual data and the combined estimates for 100 imputations ([table 2](#T2){ref-type="table"} and [supplementary materials](#SP1){ref-type="supplementary-material"}). A sensitivity analysis confirmed the effects ([table 3](#T3){ref-type="table"}) using multiple imputation (using groups, age, gender and weight at each time point), LOCF and BOCF techniques. As interaction terms were significant using all approaches, we were confident of the effects observed.

While it is not possible to separate out the components of the interdisciplinary approach, it appears more individualised advice including a focus on specific foods may have enhanced the effect. This was especially evident with the food supplemented group who continued to produce a greater weight loss at 6 months. The size of the effect and the time taken to achievement are also highly relevant to practice. The effects were similar to those reported in a systematic review of weight loss interventions which found that for combined diet and exercise interventions ranging from 12 months to 18 months, mean weight losses ranged from 0.3 kg to 5.9 kg for women and 4.2--7.3 kg for men.[@R35] Without unusual retention strategies, we found that a 3-month commitment to an intensive treatment was feasible, and in that time the intervention protocol delivered a greater proportion with a 5% weight loss target. In Western societies, it is estimated that the adult population gains 0.45 kg weight/year,[@R36] so our effects could be interpreted as even greater. Had we continued with monthly rather than quarterly clinic visits after 3 months we may have improved retention and study power, but that would meant greater healthcare costs. A simple sample size calculation based on the differences between groups for the completers at 12 months indicates that approximately 124 subjects per group would be required to complete the study for differences between the three groups to be statistically significant when adjusted for multiple comparisons.

Secondary outcomes {#s4b}
------------------

We confirmed the observation that a 5% weight loss can have an impact on disease risk factors.[@R15] Significant reductions in SBP occurred with weight loss, as expected, but this also occurred with increased physical activity, improved mental health scores and a reduction in urinary sodium, a dietary factor known to be associated with blood pressure.[@R37] The latter implies that the dietary changes went beyond that of energy restriction. As the national dietary guidelines were a reference point for all groups, differences in sodium intakes were not observed in this intention-to-treat analysis. Per protocol analyses may be able to detect whether greater changes occurred in the groups with the dietitian (I and IW) confirming effects seen in other primary care studies.[@R38] Similarly the improvements in blood glucose parameters occurred with weight loss in the presence of increased physical activity and a reduced carbohydrate load for the study cohort. Further research on the types of carbohydrate-rich foods may be informative in detecting more specific differences between groups.

The changes in blood lipids were as expected with changes in weight. The lower overall mean for total cholesterol for the IW group occurred in the presence of a significantly different dietary P:S ratio. We have previously shown that integrating walnuts in an energy controlled diet can change the dietary P:S ratio with concomitant effects on lipids.[@R39] Given that walnuts are a fat-rich food, their inclusion in the dietary modelling for the IW group would be expected to influence the overall diet profile.

Implications for practice {#s4c}
-------------------------

Practice involves an integration of evidence on many factors, and in this research we examined a number of components. We confirmed that changes in disease risk factors occurred alongside changes in body weight, physical activity, mental health scores and dietary factors known to have an impact on disease risk such as dietary sodium, fibre and fatty acid profile.[@R10] In this trial the dietitian provided face-to-face counselling with participants. Being more specific about actual foods to be consumed may be more effective and providing significant healthy food (walnuts) emphasised this point. While the effects of walnuts in the diet can be found in the literature,[@R39] there may have been synergistic effects with psychological factors in our trial. The reduced psychological avoidance of weight related issues (AAQW scores) was particularly relevant and further analyses of our data may clarify the effects of health coaching when integrated into diet and physical activity advice. In addition, and based on our previous research,[@R42] the greater initial weight loss achieved by the IW group may have influenced retention, and this may have also resulted in the higher QoL scores, but it is difficult to determine if the provision of the food supplement alone acted as the main incentive.[@R43] The greater attendance at phone coaching sessions by the IW group, which targeted skills in mindfulness and acceptance, also may have helped deal with the stress associated with achieving health goals.[@R18] It is difficult to tease out any singular effect as there is so much interdependence between behavioural factors, but this study has helped expose significant elements. The pattern of weight loss reflected reduced energy intake and increased physical activity ([table 2](#T2){ref-type="table"}), providing evidence for applying expertise in both diet and exercise.[@R44] As sources of nutrients, the food choices drove nutritional changes underpinned by the involvement of dietitians.[@R46]

Strengths and limitations {#s4d}
-------------------------

The sample comprising volunteers from the community attending a single clinic was a limitation, and, although the proportion of individuals not speaking English well in the primary recruitment area was relatively low (approximately 3%),[@R48] excluding these individuals may have further minimised access to a high-risk group. As a case study in planning services, however, the recruitment strategy gave us an indication of who might attend for these types of treatment. The study was testing an approach applicable to primary care, so the analysis was conducted on an intention-to-treat basis rather than on compliance to treatment. In addition there was a high level of control of potential confounding variables. The design where all groups received the same intensity of intervention with dietary advice referring to foods in AGHE[@R29] may have masked our ability to show true effects. In similar highly controlled circumstances it has been argued that for every kg increase in weight loss by controls, treatment effects may be reduced by about 0.3 kg[@R49].

While weight loss was observed, the lack of between-group differences in reported energy intakes may reflect inaccuracies in dietary reporting and limitations in databases for estimating food energy. For example, the available energy from walnuts has been measured as 20% less than conventional estimates,[@R50] and this may relate to other whole foods.[@R51] The between-group differences in weight loss are plausible from the literature.[@R8] Like other research in this area,[@R8] this study confirms the benefit of thinking beyond energy restriction, where other dietary factors act in synergy to influence outcomes.

The trial was aligned to translation to practice, so we did not employ enhanced retention strategies, but we know that early weight loss and age \>50 years may predict retention.[@R42] While we observed considerable participant dropout which was predominantly due to time constraints and personal reasons, participant dropout is common in weight loss trials.[@R54] We also compared a number of missing data analysis techniques via sensitivity analyses.[@R54] Research indicates that psychological and behavioural factors appear more aligned with attrition than other background participant characteristics,[@R55] something we aim to study further with this data set. In the evaluation survey of the trial, participants indicated general approval of the approach and the three most listed positive features were individual attention, the health practitioner and the education provided (data not shown). Research indicates that, as part of chronic disease management, avoidance of weight gain may reduce healthcare costs in the long term.[@R56] Four visits within the 3-month model of care could fit within the current annual Australian Medicare arrangements,[@R57] although with considerations for eligibility, and possible co-payments. These aspects all require confirmatory research. Research is also needed on whether attending for 3 months would be sufficient to achieve this initial target, acknowledging that a 'flattening' of effects after 6 months is typical and reflects metabolic and behavioural adaptations.[@R16]

This study addressed a research gap providing evidence for developing effective healthcare teams in chronic disease management.[@R20] Further analyses will be able to examine motivation and commitment barriers that both participants and healthcare teams must face. It is acknowledged that addressing long-term behaviour change is difficult in primary care,[@R58] and that a lack of motivation and incentives may hinder trials on novel lifestyle interventions.[@R59] Our trial recruited from the community, but medical supervision and communications with primary care physicians was part of the safety management, and provided insights into translation.

Conclusion {#s4e}
----------

The primary care context provides many opportunities for dealing seriously with weight management as a health issue. Excess body weight is linked to the pathology of major CNCD, and is influenced by both physiological and behavioural factors. More research with greater consolidation of interdisciplinary expertise, and establishing greater integration with medical and nursing practices will assist translation into primary care. Familiarity in standards of operation for the various professions building a full appreciation of knowledge and skills is required. Promoting opportunities to collaborate and providing guidelines[@R60] are a start to developing long-term plans.
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